Plus Therapeutics Appoints Kyle Guse To Board Of Directors, Will Lead Audit Committee

Plus Therapeutics, Inc., a clinical-stage company focused on targeted radiotherapeutics for central nervous system cancers, has appointed Kyle Guse, J.D., M.B.A., to its Board of Directors. Guse will serve as chair of the Audit Committee and join the Compensation Committee.

“Kyle’s decades of financial, transactional and operational experience in our industry will make an immediate and positive impact on Plus’ board of directors. Furthermore, in his role as audit chair, Kyle will be a force in the successful execution of Plus’s ambitious business plan and driving stockholder values,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer.

Guse brings three decades of experience in corporate leadership, law, and finance. Most recently, he served as Chief Financial Officer and General Counsel at Atossa Therapeutics, a Nasdaq-listed biotech developing breast cancer therapies. He is currently the Chief Legal Officer of DDC Enterprise Ltd., a NYSE-listed consumer foods company.

Mr. Guse commented, “Plus Therapeutics has multiple and significant opportunities in both the therapeutics and diagnostics markets with REYOBIQ™ (rhenium Re186 obisbemeda) and CNSide, and I believe it has tremendous potential to make an impact on the market. I look forward to collaborating closely with the Board and management to help bring the Company to its full potential for stockholders, practitioners, and patients.”

Guse began his career as a Certified Public Accountant at a Big 4 firm, later becoming a corporate law partner at several top international law firms. He holds a J.D. from Santa Clara University, an M.B.A. from CSU Sacramento, and a B.S. in Accounting.